Furthermore, targeting the epigenetic m6A modification in AML by inhibiting the catalytic activity of the METTL3 methyltransferase by the small-molecule inhibitor STM2457 impairs engraftment potential in murine models of AML [233]. Here, METTL3 is linked to acute myeloid leukemia.